Bintrafusp alfa with cCRT followed by bintrafusp alfa versus placebo with cCRT followed by durvalumab in patients with unresectable stage III NSCLC: A phase 2 randomized study

By sjmartinez • October 6, 2023

Vokes EE, Mornex F, Sezer A, Cheng Y, Fang J, Baz DV, Cil T, Adjei AA, Ahn MJ, Barlesi F, Felip E, Garon EB, Audhuy F, Ito R, Sato M, Eggleton SP, Martin CM, Reck M, Robinson CG, Paz-Ares L. Bintrafusp alfa with cCRT followed by bintrafusp alfa versus placebo with cCRT followed by durvalumab in patients with unresectable stage III NSCLC: A phase 2 randomized study. J Thorac Oncol. 2023 Oct 3:S1556-0864(23)02262-1. doi: 10.1016/j.jtho.2023.09.1452. Epub ahead of print. PMID: 37797733.

Tags: bifunctional, bintrafusp alfa, concurrent chemoradiotherapy, Hematology/Oncology, non-small-cell lung cancer, Publications, TGF-β

PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers

Gu Y, Ly A, Rodriguez S, Zhang H, Kim J, Mao Z, Sachdeva A, Zomorodian N, Pellegrini M, Li G, Liu S, Drakaki A, Rettig[...]

Alcohol and cannabis use associated with cardiometabolic biomarkers among “All of Us” cancer survivors

Arizpe A, Chapman TM, Rodriguez C, Carvajal A, Queen KJ, Navarro S, Ochoa-Dominguez CY, Kim SE, Toledo-Corral CM, Farias AJ. Alcohol and cannabis use associated[...]

Treatment Response Assessment According to Updated PROMISE Criteria in Patients with Metastatic Prostate Cancer Using an Automated Imaging Platform for Identification, Measurement, and Temporal Tracking of Disease

Benitez CM, Sahlstedt H, Sonni I, Brynolfsson J, Berenji GR, Juarez JE, Kane N, Tsai S, Rettig M, Nickols NG, Duriseti S. Treatment Response Assessment[...]